Epizyme amps up Series B to $40M

Epizyme has lured New Enterprise Associates into its venture capital fold and added former MedImmune CEO David Mott to the board. NEA added $8 million to the second round, bringing the total to $40 million. "Expanding our syndicate to include NEA adds another investor with significant drug-development and company building expertise as well as substantial capital resources," said Epizyme CEO Kazumi Shiosaki, PhD. "By raising more capital now, we can continue to aggressively advance our pipeline of histone methyltransferase inhibitors for various oncology indications. I look forward to working with our investors to continue to build a leading company in the promising new area of epigenetics." Mott, meanwhile, has been busy adding notches to his VC belt. He is now chairman of 3-V Biosciences and Zyngenia, a director of Ardelyx and Zosano Pharma, and serves on the advisory board of the Scripps Translational Science Institute.  

- check out Epizyme's release for more information

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.